MediMix’s Post

Have you read the recent study published in npj Breast Cancer, "Reporting on Invasive Lobular Breast Cancer in clinical trials: a systematic review?" Written by ILC researchers with input from many ILC patient advocates, the study reports that individuals with ILC and minorities are significantly underrepresented in clinical trials, which is impeding development of lobular specific treatments. LBCA is happy to have hosted the dinner among ILC patient advocates and researchers during SABCS 2022 that stimulated this research. All are invited to share this piece which shines an important spotlight on this deficit. Read the full article here: https://lnkd.in/eztZSaFu #LobularBreastCancer #ILCResearch

🔥 ASCO 2024 Plenary: Dr Kristof Cuppens (Jessa Hospital) discusses the ADRIATIC study results, showing the benefit of consolidation durvalumab following chemoradiotherapy in limited stage small-cell lung cancer, improving progression-free and overall survival. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #LungCancer #OncologyInnovation

🎥 New Insights from ESGO 2024: TTFields in Ovarian Cancer 🔬 Watch Emeritus Prof Ignace Vergote discuss the ENGOT-ov50/GOG-3029/INNOVATE-3 trial's exploration of Tumor Treating Fields (TTFields) combined with paclitaxel for treating platinum-resistant ovarian cancer. Discover key findings and what they mean for future research in this field. 👇 For all ESGO & SGO 2024 videos, find the link in the comments! #MediMix #ESGO2024 #SGO2024 #OvarianCancer #TTFields #CancerResearch

A new SOC for LS-SCLC: ADRIATIC - listen below

🔬 Insights from ASCO 2024! Prof Dr Francois Duhoux presents a pooled analysis of the DESTINY-Breast 01, 02, and 03 trials. The study highlights the efficacy of T-DXd in HER2+ metastatic breast cancer, showing significant complete response rates and their impact on progression-free and overall survival. Learn more about these findings and their clinical implications. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #BreastCancer #OncologyInnovation #HER2

Prof Nuhad Ibrahim from MD Anderson Cancer Center reveals promising Phase 1b results of the ELEKTRA trial at SABCS 2023. This innovative study explores the combination of elacestrant and abemaciclib in treating ER+ breast cancer brain metastases. The trial's early findings show a well-tolerated and safe regimen, marking a significant step towards enhancing therapeutic options for this challenging condition. Discover these vital insights. 👇 For all SABCS 2023 videos, find the link in the comments! #SABCS2023 #BreastCancer #ELEKTRATrial #OncologyInnovation

🚀 ASCO 2024 Daily Highlight: Our latest Daily Highlight focuses on critical advancements in GI cancer research. Discover key studies on metastatic colon cancer, rectal cancer and MSI-high rectal cancer, presented by Prof Hans Prenen. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #GICancer #OncologyInnovation

📝We share the #Review "Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges" 🧐by Lorenzo Guidi et al. Access the full paper here▶️ https://lnkd.in/dByNUp2W Keywords: HER2-positive breast cancer; antibody-drug conjugates; trastuzumab emtansine

OncLive has an exciting video featuring Dr. Anne Chiang, discussing how the treatment landscape for extensive-stage small cell lung cancer (ES-SCLC) has changed, thanks to data from the CASPIAN trial. The CASPIAN study investigated first-line treatments for ES-SCLC. Researchers compared different regimens, including durvalumab (an immunotherapy) combined with platinum/etoposide chemotherapy. The goal was to improve overall survival (OS) for patients facing this aggressive cancer. Be sure to watch the video! #cancer #oncology #lungcancerresearch https://lnkd.in/gEvqxrqz

At #ELCC24, we're presenting additional analysis from LIBRETTO-001, a phase I/II study of a RET kinase inhibitor in patients with RET fusion-positive non-small cell lung cancer (#NSCLC). Click here to learn more about our presentations at this year's meeting: https://e.lilly/4ajw0a4 #LungCancer #LCSM #CancerResearch